Aurobindo’s CuraTeQ Expands Biosimilars Deal With Orion For Baltic Countries
Partners Expect To Launch Products Between 2023 And 2026
• By Akriti Seth
Aurobindo’s CuraTeQ Biologics has expanded its biosimilar distribution agreement with Finnish Player Orion. After covering the Nordics, Austria, Hungary and Slovenia, the partnering companies have decided to expand to the Baltic countries, with launches slated for between 2023 and 2026.
After covering the Nordics, Austria, Hungary and Slovenia, the partnering companies will supply biosimilars to the Baltic countries. • Source: Alamy
Aurobindo Pharma USA Inc.’s CuraTeQ Biologics has announced extending its partnership with Orion Corporation to expand their biosimilar distribution agreement in Europe to the Baltic countries.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
After Amgen’s surprise launch of the first US biosimilar to Eylea last year, expectations around competition are being further upended with the news that Biocon Biologics has struck a settlement deal with Regeneron allowing it to launch its own aflibercept rival in the second half of 2026. Will other challengers follow suit?
The company did not disclose which particular drugs it secured through the deal that further boosted its portfolio that already includes more than 100 assets.
Following recent agreements signed by Hikma and Amneal, Viatris has become the latest company to reach a cash settlement resolving allegations that its practices fuelled the US’ deadly opioid epidemic.
The company did not disclose which particular drugs it secured through the deal that further boosted its portfolio that already includes more than 100 assets.
Henlius has reported progress in its development of a bevacizumab product for treating ophthalmic diseases, with its Essex-partnered HLX04-O candidate meeting its primary endpoint in a Phase III trial. Meanwhile, Outlook Therapeutics has taken another shot at getting its own ophthalmic bevacizumab approved in the US after resubmitting its filing.
